Skip to Content

Dr Reddy's Laboratories Ltd ADR RDY Stock Quote

| Rating as of

NYSE:RDY

Morningstar‘s Stock Analysis RDY

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Dr. Reddy's Posts Strong Product Launches; Maintaining $60 Fair Value Estimate

Debbie S. Wang Senior Equity Analyst

Analyst Note

| Debbie S. Wang |

No-moat Dr. Reddy’s reported strong product launches in its second quarter that offset the decline of its COVID-19-related product sales. We maintain our fair value estimate of $60 per share.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics RDY

Company Profile RDY

Business Description

Headquartered in India, Dr. Reddy’s Laboratories develops and manufactures generic pharmaceutical products sold across the world. The company specializes in low-cost, easy-to-produce small-molecule generic drugs and active pharmaceutical ingredients. Its drug portfolio in recent years has included biosimilar drug launches in select emerging markets and has shifted toward injectables and more complex generic products. Geographically, the company’s sales are well dispersed across North America, India, and other emerging markets.

Contact
8-2-337, Road No. 3, Banjara Hills
Hyderabad, TG, 500 034, India
T +91 4049002900
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Sep 30, 2022
Fiscal Year End Mar 31, 2023
Employees 24,795